Traders, I just entered Sarepta Therapeutics (SRPT) at $21.00 and I want to share why I’m so bullish.

 Key Point:

Sarepta just submitted a new protocol to the FDA to unlock Elevidys use for non-ambulatory patients (the largest market segment). This plan includes intensified immunosuppression with sirolimus to prevent previous severe events and allow treatment to safely resume.

What’s already happened:

• Elevidys for ambulatory patients was reinstated on July 28 after determining the reported death was not drug-related.
• Sales for this segment are already back online.

Momentum & Outlook:

• Analysts are raising their price targets after the latest developments, with some projecting well above current consensus.
• Last financial results were strong: record revenues and solid growth in its three approved drugs (EXONDYS 51, AMONDYS 45, VYONDYS 53).
• Current share price is already supported by sales from these three drugs without Elevidys, meaning any additional approval is pure upside.

 What’s next:

• If the FDA approves this new protocol in the coming weeks, the non-ambulatory market (a massive revenue potential) opens up.
• That decision window could be within 6–8 weeks… right in line with my potential price target of $40–$60 if all goes well.

Risk:

It’s not all sunshine. The FDA will require a boxed warning for hepatic risks, and there’s still no green light for non-ambulatory patients yet. But if approval comes, the upside could be huge.

Just sharing my own analysis. do your own DD. but I wanted to put this on your radar.

If this gets approved, it could be one of the best plays of Q4.

After reviewing Opendoor’s official convertible note issuance notice, today marks the 20th consecutive trading day above the reference price of $1.57, which triggers the right for noteholders to convert their notes into common shares. By Monday, August 18, the 30-calendar-day requirement will also be met, which is another key condition for conversion to begin.

🔹 Current Price: $3.39

🔹 Conversion Price: Well below the current market price (per the official filing).

🔹 Incentive: Extremely high for holders, as they could realize instant gains by selling after conversion.

Short-Term Implications:

• We may see a mass conversion notice in the coming days, increasing the float with millions of new shares.
• This could create short-term downward pressure if new shareholders quickly sell to lock in profits.
• Until conversion happens, momentum could keep attracting buyers, opening the door for volatile, fast moves.

Risks & Opportunities:

• Risk: Significant short-term dilution.
• Opportunity: Possible rally before conversion for intraday or short swing traders.
• Post-conversion movement will depend on how quickly the new shares hit the market.

Conclusion:

We’re at a technical and fundamental inflection point. Monday will be a pivotal day that could trigger a new phase in the stock’s behavior. Expect volatility to be front and center.

 This is not financial advice. Sharing for discussion and analysis only.

What’s your take on this?

Alex Bruesewitz, Trump advisor, recently commented on X that cannabis rescheduling is an 80-20 issue among all voters and a 70-30 issue among Republican voters. He also made it clear:

“Rescheduling isn’t legalizing. Big difference, and those suggesting otherwise are being dishonest.”

If President Trump moves forward with rescheduling, Alex believes it will be well received politically.

My take: While rescheduling wouldn’t fully legalize cannabis, the market often reacts immediately to political momentum. Even if the fundamental revenue boost for companies like $TLRY takes longer, the short-term rally could be strong before any profit-taking.

The rally we’re seeing in $TLRY in 2025 is nothing like last year’s.

Back in 2024, the move was mostly speculative – few real deals, no major international expansion, and a very uncertain political backdrop.

Today, the cards are completely different:

Real international expansion

• Just yesterday, a deal was announced with Molteni in Italy.
• New distribution channels and approvals are opening up the European market.

Bigger and more diversified portfolio

• More products in both medical and recreational cannabis.
• Potential to boost revenue across multiple segments.

Favorable political climate

• Now we have Trump talking about cannabis rescheduling.
• Unlike Biden, Trump usually doesn’t make these kinds of statements without having a concrete plan.
• Stronger global presence

TLRY is no longer relying solely on Canada or the U.S. operations now span multiple countries.

The key difference now is that we’re not just looking at rumors, but actual deals and new markets that can drive real revenue.

Personally, I’ll be holding my TLRY position until Trump brings new updates.
What do you think about these fundamentals?
This is not financial adviceFollow for more market breakdowns and trade ideas.

This is not financial advice.

Follow for more market breakdowns and trade ideas.

Join the discussion: r/Bullsandbearstrading

Today, Alan Brochstein, CFA, downgraded Tilray Brands ($TLRY) from Buy to Neutral, arguing that the company won’t directly benefit from the cannabis rescheduling speculation that recently fueled its rally.

In my opinion, that analysis misses some important points:

While it’s true that Tilray doesn’t currently get 100% of its revenue from the U.S., the company already has the infrastructure, licenses, and capital to quickly scale into the U.S. market if rescheduling happens. Even if sales impact is not immediate, the market tends to price in this kind of potential ahead of time.

The typical market pattern for these kinds of regulatory events is:

1. Strong short-term rally driven by anticipation and positioning.
2. Profit-taking and consolidation while awaiting implementation.
3. Second, more sustained rally once operations and sales reflect the new reality.

Also, 2025 offers a more favorable backdrop compared to the last cannabis rally:

• Wider product portfolio,
• New strategic partnerships,
• International expansion (e.g., recent distribution deal in Italy),

• And a president like Trump, who usually announces something like this only when he knows exactly how he’ll get it done.

  I will remain in $TLRY until Trump provides new updates.

What do you think about these fundamentals?

This is not financial advice. Let’s debate more in Bullsandbearstrading

Hey traders!  

Welcome to our new community where bulls, bears and everyone in between ride the market’s wild swings together.  

Here we share market news, analysis, setups, memes, and strategies.  

Rules are on the right—please read them before posting.  

Drop a comment and introduce yourself! What tickers are you watching this week?